Development of a 177Lu-labeled RGD derivative for targeting angiogenesis

Cancer Biotherapy and Radiopharmaceuticals

Volumn 25, Issue 6, 2010, Pages 687-691

  Ju, Chang Hwan ^a,b   Jeong, Jae Min ^a   Lee, Yun Sang ^a   Kim, Young Joo ^a   Lee, Byung Chul ^a   Lee, Dong Soo ^a   Chung, June Key ^a   Lee, Myung Chul ^a   Jeong, Seo Young ^b  

^a Seoul National University College of Medicine   (South Korea)

^b Kyung Hee University   (South Korea)

Author keywords

Angiogenesis; Lu 177; lutetium; NOTA; radionuclide therapy; RGD

Indexed keywords

2 (4' ISOTHIOCYANATOBENZYL) 1,4 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID CONJUGATE(ARGINYLGLYCYLASPARTIC ACID) LU 177; LUTETIUM 177; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID; 1,4,7-TRIAZACYCLONONANE-N,N',N''-TRIACETIC ACID; ARGINYL-GLYCYL-ASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; CHELATING AGENT; HETEROCYCLIC COMPOUND; LUTETIUM; OLIGOPEPTIDE; RADIOISOTOPE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; CANCER CELL CULTURE; COLON CANCER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; DRUG UPTAKE; GAMMA RADIATION; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANIMAL; ANIMAL ANATOMY; CHEMICAL STRUCTURE; CHEMISTRY; COLON TUMOR; DRUG DELIVERY SYSTEM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY; METABOLISM; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); SYNTHESIS; TISSUE DISTRIBUTION;

ANIMAL STRUCTURES; ANIMALS; CHELATING AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLONIC NEOPLASMS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; HETEROCYCLIC COMPOUNDS; KIDNEY; LUTETIUM; MALE; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; RADIOISOTOPES; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 78651299847     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2010.0825     Document Type: Article

References (27)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249.
2. Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science 1987;238:491.
3. Plow EF, Haas TA, Zhang L, et al. Ligand binding to in-tegrins. J Biol Chem 2000;275:21785.
4. Meyer A, Auernheimer J, Modlinger A, et al. Targeting RGD recognizing integrins: Drug development, biomaterial re-search, tumor imaging and targeting. Curr Pharm Des 2006;12:2723.
5. Brooks PC, Clark RA, Cheresh DA. Requirement of vascu-lar integrin alpha v beta 3 for angiogenesis. Science 1994; 264:569.
6. Allman R, Cowburn P, Mason M. In vitro and in vivo effects of a cyclic peptide with affinity for the alpha(nu)beta3 in-tegrin in human melanoma cells. Eur J Cancer 2000;36:410.
7. Brooks PC, Stromblad S, Klemke R, et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angio-genesis in human skin. J Clin Invest 1995;96:1815.
8. Haubner R, Wester HJ, Reuning U, et al. Radiolabeled al-pha(v)beta3 integrin antagonists: A new class of tracers for tumor targeting. J Nucl Med 1999;40:1061.
9. Haubner R. Alphavbeta3-integrin imaging: A new approach to characterise angiogenesis? Eur J Nucl Med Mol Imaging 2006;33(Suppl1):54.
10. Janssen M, Oyen WJ, Massuger LF, et al. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm 2002;17:641.
11. 99mTc-labeled cyclic RGDfK dimer: Initial evaluation for SPECT imaging of glioma integrin al-phavbeta3 expression. Bioconjug Chem 2006;17:1069.
12. Janssen ML, Oyen WJ, Dijkgraaf I, et al. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res 2002;62:6146.
13. 2. J Nucl Med 2006;47:113.
14. Moon EH, Lim ST, Jeong YJ, et al. Efficacy of I-123/I-131 metaiodobenzylguanidine scan as a single initial diagnostic modality in pheochromocytoma: Comparison with bio-chemical test and anatomic imaging. Nucl Med Mol Imaging 2009;43:436.
15. 131I-MIBG therapy in a patient with recurred malignant pheochromocytoma. Nucl Med Mol Imaging 2009;43:582.
16. Yoshimoto M, Ogawa K, Washiyama K, et al. Alpha(v) beta(3) integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide. Int J Cancer 2008;123:709.
17. 177Lu-labeled hydroxyapatite parti-cles for possible use in the therapy of liver cancer. Nucl Med Biol 2008;35:589.
18. 177Lu-DOTMP as potential agents for palliative radiotherapy of bone metastasis. Appl Radiat Isot 2008;66:1196.
19. 68Ga-labeled c(RGDyK)- isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice. J Nucl Med 2008;49:830.
20. Studer M, Meares CF. Synthesis of novel 1,4,7-triazacyclo-nonane-N,N', N"-triacetic acid derivatives suitable for protein labeling. Bioconjug Chem 1992;3:337.
21. McMurry TJ, Brechbiel M, Wu C, et al. Synthesis of 2-(p- thiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid: Application of the 4-methoxy-2,3,6-trimethylbenzene-sulfonamide protecting group in the synthesis of macrocy-clic polyamines. Bioconjug Chem 1993;4:236.
22. 188Re-labeled radio-pharmaceuticals: An overview of promising results from initial clinical trials. Cancer Biother Radiopharm 2003;18:707.
23. 177Lu for radionuclide therapy. Appl Radiat Isot 2003;59:109.
24. Jeong JM, Knapp FF Jr. Use of the Oak Ridge National Laboratory tungsten-188/rhenium-188 generator for prep-aration of the rhenium-188 HDD/lipiodol complex for trans-arterial liver cancer therapy. Semin Nucl Med 2008;38: S19.
25. 90Y suitable for targeted therapy. Nucl Med Biol 2008;35:245.
26. Cacheris WP, Nickle SK, Sherry AD. Thermodynamic study of lanthanide complexes of 1,4,7-triazacyclononane-N,N',N"-triacetic acid and 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid. Inorg Chem 1987;26:958.
27. 68Ga and investigation of in vitro properties. Nucl Med Mol Imaging 2009;43:330.